1. Home
  2. AGIO vs CIVI Comparison

AGIO vs CIVI Comparison

Compare AGIO & CIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AGIO
  • CIVI
  • Stock Information
  • Founded
  • AGIO 2007
  • CIVI 1999
  • Country
  • AGIO United States
  • CIVI United States
  • Employees
  • AGIO N/A
  • CIVI N/A
  • Industry
  • AGIO Biotechnology: Pharmaceutical Preparations
  • CIVI Oil & Gas Production
  • Sector
  • AGIO Health Care
  • CIVI Energy
  • Exchange
  • AGIO Nasdaq
  • CIVI Nasdaq
  • Market Cap
  • AGIO 2.4B
  • CIVI 2.6B
  • IPO Year
  • AGIO 2013
  • CIVI 2011
  • Fundamental
  • Price
  • AGIO $40.16
  • CIVI $26.38
  • Analyst Decision
  • AGIO Strong Buy
  • CIVI Hold
  • Analyst Count
  • AGIO 4
  • CIVI 13
  • Target Price
  • AGIO $59.33
  • CIVI $42.40
  • AVG Volume (30 Days)
  • AGIO 567.8K
  • CIVI 2.3M
  • Earning Date
  • AGIO 10-30-2025
  • CIVI 11-06-2025
  • Dividend Yield
  • AGIO N/A
  • CIVI 7.59%
  • EPS Growth
  • AGIO N/A
  • CIVI N/A
  • EPS
  • AGIO N/A
  • CIVI 7.93
  • Revenue
  • AGIO $44,791,000.00
  • CIVI $4,815,808,000.00
  • Revenue This Year
  • AGIO $25.57
  • CIVI N/A
  • Revenue Next Year
  • AGIO $153.24
  • CIVI N/A
  • P/E Ratio
  • AGIO N/A
  • CIVI $3.32
  • Revenue Growth
  • AGIO 36.26
  • CIVI 0.23
  • 52 Week Low
  • AGIO $23.42
  • CIVI $22.79
  • 52 Week High
  • AGIO $62.58
  • CIVI $55.35
  • Technical
  • Relative Strength Index (RSI)
  • AGIO 45.66
  • CIVI 35.92
  • Support Level
  • AGIO $38.90
  • CIVI $25.78
  • Resistance Level
  • AGIO $44.10
  • CIVI $27.73
  • Average True Range (ATR)
  • AGIO 1.72
  • CIVI 1.05
  • MACD
  • AGIO -0.44
  • CIVI -0.09
  • Stochastic Oscillator
  • AGIO 24.58
  • CIVI 17.95

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

About CIVI Civitas Resources Inc.

Civitas Resources Inc is an independent exploration and production company engaged in the acquisition, development, and production of oil and associated liquids-rich natural gas in the Rocky Mountain region, in the Denver-Julesburg Basin of Colorado - DJ Basin. The company's operations are focused on developing the horizontal Niobrara and Codell formations that have a low-cost structure, mature infrastructure, production efficiencies, multiple producing horizons, multiple service providers, established reserves, and prospective drilling opportunities.

Share on Social Networks: